The role of mitochondrial proteases in leukemic cells and leukemic stem cells

Stem Cells Transl Med. 2020 Dec;9(12):1481-1487. doi: 10.1002/sctm.20-0142. Epub 2020 Aug 5.

Abstract

The biological function of most mitochondrial proteases has not been well characterized. Moreover, most of the available information on the normal function of these proteases has been derived from studies in model organisms. Recently, the mitochondrial proteases caseinolytic protease P (CLPP) and neurolysin (NLN) have been identified as therapeutic targets in acute myeloid leukemia (AML). Both proteases are overexpressed in approximately 40% of AML patients. Mechanistically, CLPP and NLN maintain the integrity of the mitochondrial respiratory chain: CLPP cleaves defective respiratory chain proteins, while NLN promotes the formation of respiratory chain supercomplexes. In this review, we highlight the functional consequences of inhibiting and activating mitochondrial proteases and discuss their potential as therapeutic targets in AML.

Keywords: acute myelogenous leukemia (AML); cancer; hematologic malignancies; hematopoietic stem cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Proliferation
  • Humans
  • Leukemia, Myeloid, Acute / genetics*
  • Mitochondria / metabolism*
  • Neoplastic Stem Cells / metabolism*
  • Peptide Hydrolases / metabolism*

Substances

  • Peptide Hydrolases

Grants and funding